AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04767854 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OA school
Description: Patient education according to guidelines, with information about e.g. disease progression, symptoms, treatment, exercise, self-care techniques and dietary information
Study NCT04767854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Training mobile health application
Description: Individually tailored home exercise programs delivered through a mobile health application
Study NCT04767854 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Individually tailored exercise programs conducted in weekly supervised individual or group sessions
Study NCT05619380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy treatment
Description: Three different physiotherapy treatments will be used for, to reduce pain and tension in the masseter muscles. The assessment of pain intensity on the VAS scale will be assessed each time after the therapy. After the 5th and 10th day of therapy, it will be measured ROM and sEMG.
Study NCT04645134 — intervention group
Intervention type: BEHAVIORAL
Intervention: Brain Health Assessments
Description: The investigators are enrolling up to 28 healthy, older adults (ages 65-85 y, BMI 20-35 kg/m2) stratified by current physical activity level (equal inactive vs. equal highly active). Each physical activity group (inactive and highly active) will undergo a blood draw, body composition, resting metabolic rate, cognitive testing, and magnetic resonance (MR) imaging.
Study NCT06260475 — intervention group
Intervention type: PROCEDURE
Intervention: Aortobifemoral bypass
Description: Open surgery with aortic and iliac reconstruction
Study NCT06260475 — intervention group
Intervention type: PROCEDURE
Intervention: aortoiliac stenting
Description: Endovascular reconstruction of aortic and iliac arterial obstruction:~Balloon angioplasty may be performed initially to dilate the narrowed segment of the iliac artery.~Subsequently, a stent delivery system is advanced over the wire and positioned across the lesion.~The stent is deployed under fluoroscopic guidance to expand and scaffold the diseased artery, restoring blood flow.~Vascular - iliac dedicated Stent - any brand
Study NCT06404840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab (400 mg, iv, d1, qw)
Study NCT06404840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG chemotherapy
Description: (gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
Study NCT05477992 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular embolization
Description: Embolisation is an effective measure to reduce intraoperative bleeding for vascular tumours of the head and neck. It is often carried out from 24 to 72 hours prior to the surgical resection to allow time for maximal thrombosis of the occluded vessels and prevent recanalisation of the occluded arteries or formation of collateral arterial channels.
Study NCT05674292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia Violet Zerona Z6
Description: 405nm violet diode low level laser device
Study NCT04969809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound of the jugular veins
Description: Ultrasound of the jugular veins to assess the thickness of the carotid intima media
Study NCT04969809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: addition of phenylalanine-free protein substitutes
Description: addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
Study NCT06545812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid injection (ESI)
Description: Minimally invasive methods such as epidural steroid injection (ESI) with corticosteroids like Methylprednisolone, Levobupivacaine and Lidocaine according to the protocol of the institution. They reduce inflammation by inhibiting pro-inflammatory mediators and causing a reversible local anesthetic effect.
Study NCT06545812 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy for disc herniation
Description: BTL Laser therapy, BTL ultrasound therapy and BTL Transcutaneous electrical nerve stimulation - TENS
Study NCT04438382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Given IV
Study NCT04438382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin Therapy
Description: Given IV
Study NCT04438382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO
Study NCT04438382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Given IV or PO
Study NCT05009381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stylage XXL at enrollment
Description: Injection in the chin at enrollment
Study NCT05009381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stylage XXL at Month 6
Description: Injection in the chin 6 months after randomization
Study NCT05160311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Medical Treatment (OMT)
Description: Optimized Medical Drug Treatment
Study NCT05160311 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Optimized Medical Treatment (OMT)
Description: Optimized Medical Drug Treatment
Study NCT05160311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent (DES) Coronary Angioplasty
Description: Percutaneous Angioplasty with DES
Study NCT04882189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Images of the corneal endothelium will be obtained using specular microscopy at 1- and 3-months post cataract surgery.
Study NCT05122741 — intervention group
Intervention type: DRUG
Intervention: P2Y12 Potent Inhibitor + Aspirin for STEMI patients
Description: Patients will undergo primary percutaneous coronary intervention and DAPT with potent P2Y12 inhibitor (ticagrelor or prasugrel + aspirin)
Study NCT05122741 — intervention group
Intervention type: DRUG
Intervention: Clopidogrel + Aspirin for CCS patients
Description: Patients will undergo elective percutaneous coronary intervention and DAPT with non-potent P2Y12 inhibitor (clopidogrel + aspirin)
Study NCT05194956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoral scan
Description: An intraoral scan is multiple images taken using an intraoral scanning device which results in a digital mould being taken of the participants mouth and bite. It works by systematically placing the scanner tip over the teeth and gums, whilst it constructs an image on screen.
Study NCT05194956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alginate impressions
Description: Alginate impressions are the conventional method of creating dental moulds for orthodontic records. A plastic tray is filled with an alginate material, which is placed into the mouth to take a mould of the teeth. This requires two moulds for both top and bottom arches. In addition, the participant would also bite into a warm piece of wax to record their bite.
Study NCT06417866 — intervention group
Intervention type: OTHER
Intervention: informed consent
Description: standard verbal and written informed consent
Study NCT06417866 — intervention group
Intervention type: OTHER
Intervention: spine model
Description: standard verbal and written informed consent + visual spine model
Study NCT05525780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB-5001
Description: Depending on the cohort, volume will be varied to administer.
Study NCT05525780 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched volume of placebo product will be administered to each subject in each cohort.
Study NCT05525780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral cohort
Description: Single dose of Aricept tablet
Study NCT04674735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APSLXR
Description: Oral coated tablets once a day for 60 days.
Study NCT05508945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermabond Prineo Skin Closure System
Description: synthetic mesh patch is positioned and lightly pressed over 50% of the surgical incision. 2-octyl cyanoacrylate liquid adhesive is evenly applied over the mesh and allowed to dry
Study NCT05508945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: silk
Description: SERI surgical scaffold with dermaFLEX backing is positioned over the remaining 50% of the surgical incision
Study NCT05508945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Steri-Strip
Description: non-woven rayon with adhesive backing is applied to 50% of the surgical incision.
Study NCT06213064 — intervention group
Intervention type: BEHAVIORAL
Intervention: Study Product, THC Product, Placebo
Description: Participants will complete up to a seven week study consisting of screening period, baseline period, up to a 21-day product use period with a total of 9 product use sessions. Screening assessments, baseline questions, product use period questionnaires, adverse event reporting, and end of study experience survey data will be collected. This study will be conducted remotely and will use a web-based data collection platform, Consumer Health Learning and Organizing Ecosystem (Chloe), by People Science where participants will complete study assessments using the Chloe app during the course of the study. Participants will receive the study product during the baseline period. Demographic and medical history data will be collected for the study.
Study NCT05286437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral lenvatinib + Intravenous (IV) pembrolizumab + Oral letrozole
Description: Lenvatinib and letrozole will be given orally (PO) daily from Day -14, while pembrolizumab will be administered intravenously during week 1 of each 6-weekly cycle from Cycle 1 Day 1 (C1D1), with daily lenvatinib and letrozole.
Study NCT04842526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib and irinotecan combined with temozolomide
Description: Anlotinib, 7mg/m2, PO, was given for 14 days and stopped for 7 days; Irinotecan, 50mg/m2, D1-5, IV; Temozolomide, 100mg/m2, d1-5, PO; Three weeks is a cycle.
Study NCT05685953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccine OC-007
Description: Plasmid DNA vaccine
Study NCT05685953 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% NaCl solution
Study NCT06183671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX09 or placebo SAD
Description: For Part 1 SAD: JX09/placebo in capsule will be administered as a single oral dose. The nominal dose escalation scheme for the cohorts is 1, 3, 10, 30, 100, and 300 mg.
Study NCT06183671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX09 or placebo MAD
Description: For Part 2 MAD: JX09/placebo in capsule will be administered for 11 days (once daily) The nominal dose escalation scheme for the cohorts is 2, 5, 10 and 20 mg.
Study NCT06183671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JX09
Description: For Part 3 FE: JX09 in capsule will be administered as a two single oral doses separated by 15 days. The nominal dose is 10 mg.
Study NCT04969224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed dose combination (FDC) tablet for oral administration.
Study NCT04969224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study NCT04834063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Zinc a level
Description: Diagnostic test
Study NCT04834063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum selenium level
Description: Diagnostic test
Study NCT04834063 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan measurement
Description: Diagnostic test
Study NCT05895968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior cervical surgery
Description: The patients were operated by the posterior cervical surgery, which were used with the barbed to suture the deep fascia.
Study NCT05639998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAXIN(BBV152)
Description: COVAXIN® on day 0 and on day 28 via the intramuscular route in GROUP 1. COVAXIN® (Intramuscular) on day 0 and BBV154 (Intranasal) day 28:GROUP 2
Study NCT05639998 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBV154 Intranasal Vaccine
Description: BBV154 (Intranasal) on day 0 and COVAXIN® (Intramuscular) on day 28: GROUP 3 BBV154 on day 0 and on day 28 via the intranasal route: GROUP 4
Study NCT06546761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography and FFRct analysis
Description: A new non-invasive cardiac diagnostic test, coronary CT-derived fractional flow reserve (FFRCT) provides a unified anatomic and functional assessment of coronary artery disease which can reliably identify ischemia-producing coronary lesions. FFRCT accurately reflects invasively measured FFR and can help guide patient management and coronary revascularization decisions.
Study NCT05819047 — intervention group
Intervention type: DEVICE
Intervention: Functional test with a haptic device
Description: Volunteers will complete two tests based on the Nine Hole Peg Test with a haptic device.
Study NCT06268496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serum formula 2039125 03
Description: application twice a day of the tested product (in the morning and evening) to the face for 3 months
Study NCT05538923 — intervention group
Intervention type: OTHER
Intervention: No intervention was given to the patients
Description: This study was an observational epidemiological study.
Study NCT05000853 — intervention group
Intervention type: DRUG
Intervention: Iron Carboxymaltose
Description: Iron supplementation when is needed according to usual care
Study NCT05229952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-oxalate controlled diet
Description: Participants will consume a diet that is controlled in its contents of protein, carbohydrates, fat, calcium, oxalate, vitamin C and sodium for 5 days. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.
Study NCT05229952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primed, continuous intravenous infusion of 13C2-oxalate
Description: Participants will receive a continuous intravenous administration of carbon-13 oxalate, a naturally occurring form of oxalate, over the course of several hours until steady-state is achieved, using an IV catheter, while remaining fasting.
Study NCT06730035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood analysis
Description: This is an experimental analysis on tissues (peripheral blood) and exploratory, which is why the enrollment of a limited number of patients has been planned. The results obtained from the study should not be considered conclusive but rather as generators of research hypotheses for potential subsequent studies to be conducted on larger populations. The qualitative and quantitative characteristics of the vesicles and their miRNA content will be analyzed descriptively.
Study NCT06731231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are glucose lowering agents used in the treatment of type 2 DM by improving glycemic control, weight reduction, blood pressure control and albuminuria. the use of SGLT2i as a cardiorenal protective tool may be of particular value in renal transplant patients due to the risk of multiple comorbidities such as diabetes and hypertension. Recently, sodium-glucose transport protein 2 inhibitors (SGLT2i) emerged as a new class of therapeutics with beneficial effects on both cardiovascular (CV) and kidney outcomes in patients with diabetic kidney disease, nondiabetic proteinuric chronic kidney disease (CKD), and heart failure with and without diabetes in patients with native kidneys
Study NCT06731257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: virtual ward early discharge
Description: Patients who are randomised to the study group will receive a blood pressure monitor and instructions on how to use the device and transfer data to the study team. The study nurses will contact the patient every day for 3 days following their discharge and perform an virtual ward round assessment by telephone (see table). This will determine whether the patient continues to be monitored via the virtual ward, or whether they need to be referred to the clinical team. They will be issued with an emergency contact number out of hours (coronary care unit LGI) and the nursing hub will operate from 8am to 5pm 7 days a week. They will be referred to the community cardiac rehabilitation service whilst on the pathway.
Study NCT06731829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-9231
Description: HRS-9231
Study NCT06731829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadobutrol
Description: Gadobutrol
Study NCT06730191 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: soft tissue graft covering immediate dental implant
Description: soft tissue graft covering immediate dental implant
Study NCT06014125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychoeducative program
Description: The tele-education program consists of 5 sessions and is designed to adapt to changes in depressive symptoms over time. Each session will last an average of 60 minutes. They will be scheduled every week for 5 weeks.~The first session is devoted to educational diagnosis, with identification of the patient's needs and any barriers to treatment.~The second session will focus on personalised hygienic and dietary measures. A third session will focus on identifying the symptoms of depression, with a particular focus on suicidal ideation and the causes of depression. The role of family and friends will also be discussed.~A fourth session will be devoted to providing clear information on antidepressants, with particular attention to the duration of treatment.~The aim of the final session is to identify what has been learned and to clarify any questions before drawing up a joint summary of the work done, which will be sent to the patient's GP with his or her consent.
Study NCT04837105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious game ARROW CP
Description: ARROW CP is developed for Microsoft Hololens headset. Feedback on gait performance are delivering to the participant in real time and with delay. Participants have to walk at their maximal speed during sprint session.
Study NCT04837105 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill
Description: Participant walk on a treadmill at 80% of their maximal speed during maximum 20 minutes (+5 min warm-up / 5 min cool-down)
Study NCT06228833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: monopolar radiofrequency
Description: Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face
Study NCT06228833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: monopolar radiofrequency
Description: Each subject underwent monopolar radiofrequency treatment (Thermage FLX ™ ) on both sides of the face
Study NCT06228833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SkinCeuticals A.G.E and Skinceuticals CE FERULIC
Description: Test Side receives SkinCeuticals A.G.E and Skinceuticals CE FERULIC
Study NCT06228833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cream
Description: Control Side applies Standard Cream
Study NCT05529316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An anti-CTLA-4 monoclonal antibody
Study NCT05529316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: An anti-PD-1 monoclonal antibody
Study NCT06533267 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic nasopharyngectomy followed close follow-up
Description: Radical resection of primary lesion using nasal endoscopy.~After the treatment, the electronic nasal endoscopy was reviewed every two weeks to determine the healing of the wound, whether there was tumor recurrence, until the surgical wound was completely healed. The patients were followed up at least once every three months from the first year to the third year, at least once every six months from the fourth year to the fifth year, and at least once every year after five years.
Study NCT06533267 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated Radiotherapy
Description: GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy.~After treatment, patients were followed up every 3-6 months from the first year to the third year, every 6-12 months from the fourth year to the fifth year, and at least once a year after five years.
Study NCT05433272 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain
Description: The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.
Study NCT05433272 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.